EVOK'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
Evoke Pharma Inc EVOK'ün son çeyrekteki geliri nasıl performans gösterdi?
Evoke Pharma Inc'in gelir tahmini nedir?
Evoke Pharma Inc'in kazanç kalite puanı nedir?
Evoke Pharma Inc kazançlarını ne zaman rapor eder?
Evoke Pharma Inc'in beklenen kazançları nelerdir?
Evoke Pharma Inc kazanç beklentilerini aştı mı?
Önemli İstatistikler
Önceki Kapanış
$11
Açılış fiyatı
$10.98
Günün Aralığı
$10.98 - $11
52 haftalık aralık
$1.94 - $11
İşlem hacmi
47.0K
Ort.Hacim
167.3K
EPS (TTM)
-1.92
Dividend yield
--
Piyasa Değeri
$18.9M
EVOK nedir?
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. The company is headquartered in Solana Beach, California and currently employs 3 full-time employees. The company went IPO on 2013-09-25. The company develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. The company has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.